COMPANY SHOWCASE: Owen Mumford Pharmaceutical Services

To Issue 138


Citation: “Company Showcase: Owen Mumford Pharmaceutical Services”. ONdrugDelivery, Issue 138 (Oct 2022), pp 104.

With more than 70 years’ experience in medical devices, Owen Mumford Pharmaceutical Services is a division of Owen Mumford. Its global presence extends from its UK head office and manufacturing facilities in the UK and Malaysia to subsidiaries in the US, Germany and France. Its product portfolio includes single and multi-dose reusable and disposable autoinjectors, pens and syringes for subcutaneous and intramuscular administration. Its flagship products include the UniSafe® platform (Figure 1), a springfree, passive safety device for 1 mL and 2.25 mL prefilled syringes. UniSafe 1 mL has regulatory approval as a combination product in Asia and Europe, where it is also in patient use.

Figure 1: The UniSafe® platform is a spring-free, passive safety device for 1 mL and 2.25 mL prefilled syringes.

The company’s most recent innovation is the two-step disposable autoinjector, Aidaptus® (Figure 2), which can be used for both 1 mL and 2.25 mL syringes in the same base device.

Figure 2: Aidaptus® is a two-step disposable autoinjector that can be used for both 1 mL and 2.25 mL syringes in the same base device.

Aidaptus can readily adapt to different fill volumes using auto-adjust plunger technology, providing a solution for formulation changes during development and lifecycle management.

Aidaptus has an innovative, patient centric design with automatic needle insertion that provides a simple and consistent user experience. The stopper sensing technology, coupled with the independent, two-phase needle insertion and drug delivery, significantly reduces any impact forces on the syringe, mitigating the risk of syringe breakages during use.

With a needle that is shielded before, during and after use, Aidaptus provides reassurance to users who are new to autoinjectors, as well as those who experience needle phobia. It can also give users confidence that the injection has been successfully completed with an audible notification at the start and end of the procedure.

Owen Mumford Pharmaceutical Services has an exclusive agreement with Stevanato Group, a global provider of drug containment, drug delivery and diagnostic solutions. Stevanato is its manufacturing partner for the Aidaptus autoinjector, moulding the components, and providing final and subassembly equipment. The collaboration aims to reduce supply chain complexity and reduce risk in combination product development for pharmaceutical partners.

Owen Mumford Pharmaceutical Services also has an alliance with Noble, providing patient-focused training devices for both UniSafe and Aidaptus.

Owen Mumford Pharmaceutical Services’ products are supported by its services, and the company works with its pharmaceutical partners every step of the way, assisting them throughout their combination product development.